BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 32620606)

  • 1. Modulation of Estrogen α and Progesterone Receptors in Triple Negative Breast Cancer Cell Lines: The Effects of Vorinostat and Indole-3-Carbinol In Vitro.
    Nouri Emamzadeh F; Word B; Cotton E; Hawkins A; Littlejohn K; Moore R; Miranda-Carbon G; Orish CN; Lyn-Cook B
    Anticancer Res; 2020 Jul; 40(7):3669-3683. PubMed ID: 32620606
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Indole-3-carbinol and its N-alkoxy derivatives preferentially target ERα-positive breast cancer cells.
    Caruso JA; Campana R; Wei C; Su CH; Hanks AM; Bornmann WG; Keyomarsi K
    Cell Cycle; 2014; 13(16):2587-99. PubMed ID: 25486199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reactivation of estrogen receptor α by vorinostat sensitizes mesenchymal-like triple-negative breast cancer to aminoflavone, a ligand of the aryl hydrocarbon receptor.
    Stark K; Burger A; Wu J; Shelton P; Polin L; Li J
    PLoS One; 2013; 8(9):e74525. PubMed ID: 24058584
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sensitizing Triple Negative Breast Cancer to Tamoxifen Chemotherapy via a Redox-Responsive Vorinostat-containing Polymeric Prodrug Nanocarrier.
    Ma W; Sun J; Xu J; Luo Z; Diao D; Zhang Z; Oberly PJ; Minnigh MB; Xie W; Poloyac SM; Huang Y; Li S
    Theranostics; 2020; 10(6):2463-2478. PubMed ID: 32194813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Indole-3-carbinol selectively uncouples expression and activity of estrogen receptor subtypes in human breast cancer cells.
    Sundar SN; Kerekatte V; Equinozio CN; Doan VB; Bjeldanes LF; Firestone GL
    Mol Endocrinol; 2006 Dec; 20(12):3070-82. PubMed ID: 16901971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HDAC inhibition does not induce estrogen receptor in human triple-negative breast cancer cell lines and patient-derived xenografts.
    de Cremoux P; Dalvai M; N'Doye O; Moutahir F; Rolland G; Chouchane-Mlik O; Assayag F; Lehmann-Che J; Kraus-Berthie L; Nicolas A; Lockhart BP; Marangoni E; de Thé H; Depil S; Bystricky K; Decaudin D
    Breast Cancer Res Treat; 2015 Jan; 149(1):81-9. PubMed ID: 25503779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Androgen Receptor Biology in Triple Negative Breast Cancer: a Case for Classification as AR+ or Quadruple Negative Disease.
    Barton VN; D'Amato NC; Gordon MA; Christenson JL; Elias A; Richer JK
    Horm Cancer; 2015 Dec; 6(5-6):206-13. PubMed ID: 26201402
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The indole-3-carbinol cyclic tetrameric derivative CTet inhibits cell proliferation via overexpression of p21/CDKN1A in both estrogen receptor-positive and triple-negative breast cancer cell lines.
    De Santi M; Galluzzi L; Lucarini S; Paoletti MF; Fraternale A; Duranti A; De Marco C; Fanelli M; Zaffaroni N; Brandi G; Magnani M
    Breast Cancer Res; 2011 Mar; 13(2):R33. PubMed ID: 21435243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Triple-negative breast cancer molecular subtyping and treatment progress.
    Yin L; Duan JJ; Bian XW; Yu SC
    Breast Cancer Res; 2020 Jun; 22(1):61. PubMed ID: 32517735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epigenetic restoration and activation of ERβ: an inspiring approach for treatment of triple-negative breast cancer.
    Salahuddin A; Ghanem H; Omran GA; Helmy MW
    Med Oncol; 2022 Jul; 39(10):150. PubMed ID: 35843988
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estrogen receptor β selective agonists reduce invasiveness of triple-negative breast cancer cells.
    Hinsche O; Girgert R; Emons G; Gründker C
    Int J Oncol; 2015 Feb; 46(2):878-84. PubMed ID: 25420519
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phenotypic characterization of circulating tumor cells in triple negative breast cancer patients.
    Agelaki S; Dragolia M; Markonanolaki H; Alkahtani S; Stournaras C; Georgoulias V; Kallergi G
    Oncotarget; 2017 Jan; 8(3):5309-5322. PubMed ID: 28029660
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Application of Non-Invasive Apoptosis Detection Sensor (NIADS) on Histone Deacetylation Inhibitor (HDACi)-Induced Breast Cancer Cell Death.
    Hsu KW; Huang CY; Tam KW; Lin CY; Huang LC; Lin CL; Hsieh WS; Chi WM; Chang YJ; Wei PL; Chen ST; Lee CH
    Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29393914
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Triple negative breast cancer: special histological types and emerging therapeutic methods.
    Cao L; Niu Y
    Cancer Biol Med; 2020 May; 17(2):293-306. PubMed ID: 32587770
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estrogen receptor-α36 is involved in icaritin induced growth inhibition of triple-negative breast cancer cells.
    Wang X; Zheng N; Dong J; Wang X; Liu L; Huang J
    J Steroid Biochem Mol Biol; 2017 Jul; 171():318-327. PubMed ID: 28529129
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of molecular subtype on breast cancer recurrence in young women treated with contemporary adjuvant therapy.
    Alabdulkareem H; Pinchinat T; Khan S; Landers A; Christos P; Simmons R; Moo TA
    Breast J; 2018 Mar; 24(2):148-153. PubMed ID: 28707744
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epigenetic silencing of triple negative breast cancer hallmarks by Withaferin A.
    Szarc Vel Szic K; Declerck K; Crans RAJ; Diddens J; Scherf DB; Gerhäuser C; Vanden Berghe W
    Oncotarget; 2017 Jun; 8(25):40434-40453. PubMed ID: 28467815
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of N-(Naphtho[1,2-b]Furan-5-Yl) Benzenesulfonamides as Novel Selective Inhibitors of Triple-Negative Breast Cancer (TNBC).
    Chen Y; Tang Y; Mao B; Li W; Jin H; Zhang L; Liu Z
    Molecules; 2018 Mar; 23(3):. PubMed ID: 29547591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Perspectives on Epidermal Growth Factor Receptor Regulation in Triple-Negative Breast Cancer: Ligand-Mediated Mechanisms of Receptor Regulation and Potential for Clinical Targeting.
    Williams CB; Soloff AC; Ethier SP; Yeh ES
    Adv Cancer Res; 2015; 127():253-81. PubMed ID: 26093903
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Both bulk and cancer stem cell subpopulations in triple-negative breast cancer are susceptible to Wnt, HDAC, and ERα coinhibition.
    Sulaiman A; Sulaiman B; Khouri L; McGarry S; Nessim C; Arnaout A; Li X; Addison C; Dimitroulakos J; Wang L
    FEBS Lett; 2016 Dec; 590(24):4606-4616. PubMed ID: 27859250
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.